Literature DB >> 1968963

Nasogastric and intravenous infusions of (+)-4-propyl-9-hydroxynaphthoxazine (PHNO) in Parkinson's disease.

R J Coleman1, N P Quinn, M Traub, C D Marsden.   

Abstract

(+)-4-propyl-9-hydroxynaphthoxazine (PHNO) is a new dopamine agonist which is capable of producing a sustained response in parkinsonian patients with "on-off" fluctuations when given as a continuous infusion either nasogastrically or intravenously. These data suggest that a sustained release formulation of PHNO may provide a significant, new treatment for patients with "on-off" fluctuations.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 1968963      PMCID： PMC487944          DOI： 10.1136/jnnp.53.2.102

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


  13 in total

1.  Controlled release levodopa treatment of motor fluctuations in Parkinson's disease.

Authors:  J L Juncos; G Fabbrini; M M Mouradian; C Serrati; A M Kask; T N Chase
Journal:  J Neurol Neurosurg Psychiatry       Date:  1987-02       Impact factor: 10.154

2.  MK 458, a selective and potent D2 receptor agonist in advanced Parkinson's disease.

Authors:  A Lieberman; L Chin; G Baumann
Journal:  Clin Neuropharmacol       Date:  1988-06       Impact factor: 1.592

3.  Antiparkinsonian activity of a single oral dose of PHNO.

Authors:  F Grandas; N Quinn; P Critchley; A Rohan; C D Marsden; S M Stahl
Journal:  Mov Disord       Date:  1987       Impact factor: 10.338

4.  Subcutaneous apomorphine in parkinsonian on-off oscillations.

Authors:  C M Stibe; A J Lees; P A Kempster; G M Stern
Journal:  Lancet       Date:  1988-02-20       Impact factor: 79.321

5.  The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport.

Authors:  J G Nutt; W R Woodward; J P Hammerstad; J H Carter; J L Anderson
Journal:  N Engl J Med       Date:  1984-02-23       Impact factor: 91.245

6.  On-off fluctuations in Parkinson's disease. A clinical and neuropharmacological study.

Authors:  R J Hardie; A J Lees; G M Stern
Journal:  Brain       Date:  1984-06       Impact factor: 13.501

7.  The antiparkinsonian actions and pharmacokinetics of transdermal (+)-4-propyl-9-hydroxynaphthoxazine (+PHNO): preliminary results.

Authors:  R J Coleman; K W Lange; N P Quinn; A E Loper; J V Bondi; M Hichens; S M Stahl; C D Marsden
Journal:  Mov Disord       Date:  1989       Impact factor: 10.338

8.  Lisuride infusion pump: a device for the treatment of motor fluctuations in Parkinson's disease.

Authors:  J A Obeso; M R Luquin; J M Martínez-Lage
Journal:  Lancet       Date:  1986-03-01       Impact factor: 79.321

9.  Pharmacologic profile of a novel potent direct-acting dopamine agonist, (+)-4-propyl-9-hydroxynaphthoxazine [(+)-PHNO].

Authors:  G E Martin; M Williams; D J Pettibone; G G Yarbrough; B V Clineschmidt; J H Jones
Journal:  J Pharmacol Exp Ther       Date:  1984-09       Impact factor: 4.030

10.  Controlled-release levodopa/carbidopa. I. Sinemet CR3 treatment of response fluctuations in Parkinson's disease.

Authors:  J M Cedarbaum; L Breck; H Kutt; F H McDowell
Journal:  Neurology       Date:  1987-02       Impact factor: 9.910
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.